reviewTop 1% cited
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Cancer Letters · 2020 · Vol. 500 · pp. 1–10
Chenglong Chen(Beijing Chest Hospital)Lu Xie(Peking University)Tingting Ren(Beijing Chest Hospital)Yi Huang(Peking University People's Hospital)Jie Xu(Peking University)Wei Guo✉(Peking University)
CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersOsteosarcomaMedicineImmunotherapyMalignancyClinical trialChemotherapyOncologyMetastasisMechanism (biology)Cancer
MeSH terms
HumansImmunotherapyNeoplasm Recurrence, LocalPrognosisOsteosarcomaBiomarkers, TumorTumor Microenvironment
Funding
- National Natural Science Foundation of China
Citations
543
FWCI
19.50
field-weighted impact
References
163
Percentile
100%
vs. same field & year
Citations per year
References
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Experimental Cell Research · 2005 · 1,053 citations
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Science Translational Medicine · 2014 · 2,472 citations
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Science Translational Medicine · 2013 · 2,062 citations
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
The Journal of Experimental Medicine · 1995 · 2,186 citations
Cancer statistics, 2018
CA A Cancer Journal for Clinicians · 2018 · 16,944 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.